Adaptimmune Therapeutics (ADAP) Tops Q2 EPS by 16c

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q2 EPS of ($0.02), $0.16 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $5.13 million versus the consensus estimate of $9.25 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.

You May Also Be Interested In

• Citigroup (C) Tops Q2 EPS by 42c
• UBS Reiterates Neutral Rating on Wingstop (WING), Expects Q2 to Reflect Pressured Sales Trends
• Cantor Fitzgerald: MKS Instruments (MKSI) 'Remains Our Top Pick Within the SMID Cap Space'